DL-3-tert-butoxycarbonylamino-4-hydroxy-butyric acid methyl ester | 942297-60-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: DL-3-tert-butoxycarbonylamino-4-hydroxy-butyric acid methyl ester
• 英文别名: Methyl 3-((tert-butoxycarbonyl)amino)-4-hydroxybutanoate；methyl 4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
• CAS: 942297-60-1
• 化学式: C₁₀H₁₉NO₅
• 分子量: 233.265
• InChiKey: ZZDVXWXHEXVLNH-UHFFFAOYSA-N

物化性质

• 沸点：
  364.6±37.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  DL-3-tert-butoxycarbonylamino-4-hydroxy-butyric acid methyl ester 在 sodium azide 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 DL-4-azido-3-tert-butoxycarbonylamino-butyric acid methyl ester
  参考文献：
  名称：

  Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

  摘要：

  An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.04.069
• 作为产物：
  描述：

  2-(叔丁氧基羰基氨基)-4-甲氧基-4-氧代丁酸 在 氯甲酸乙酯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.5h， 以35%的产率得到DL-3-tert-butoxycarbonylamino-4-hydroxy-butyric acid methyl ester
  参考文献：
  名称：

  Heteroarylpyrrolopyridinones active as kinase inhibitors

  摘要：

  由式（I）表示的化合物 其中A，R1，R2，R3，R4，R5和R6如规范中定义，或其药用可接受盐或溶剂，其组合物和使用方法。

  公开号：

  US20070142415A1

文献信息

• Novel compounds that are useful for improving pharmacokinetics
  申请人：Kempf J. Dale

  公开号：US20060199851A1

  公开（公告）日：2006-09-07

  Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.

  公式1的新化合物或其药用可接受的盐可以抑制细胞色素P450单加氧酶。
• Heteroarylpyrrolopyridinones active as kinase inhibitors
  申请人：Vanotti Ermes

  公开号：US20070142415A1

  公开（公告）日：2007-06-21

  Compounds represented by formula (I) wherein A, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification or a pharmaceutically acceptable salt or solvate thereof, compositions thereof, and methods of use thereof.

  由式（I）表示的化合物 其中A，R1，R2，R3，R4，R5和R6如规范中定义，或其药用可接受盐或溶剂，其组合物和使用方法。
• NOVEL QUINOLINE -SUBSTITUTED COMPOUND
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20160194332A1

  公开（公告）日：2016-07-07

  An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.

  本发明的目标是提供一种具有EGFR抑制作用和细胞生长抑制作用的新化合物，以及一种基于EGFR抑制作用的用于预防和/或治疗癌症的药物。本发明提供以下式（I）所代表的化合物或其盐。
• [EN] 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE<br/>[FR] COMPOSÉS HÉTÉROARYLES À 5 CHAÎNONS CONTENANT UNE FRACTION HYDROXAMATE ET LEUR UTILISATION
  申请人：UNIV LILLE

  公开号：WO2020148403A1

  公开（公告）日：2020-07-23

  The present invention is directed to 5-membered heteroaryl compounds containing a hydroxamate moiety of Formula I, pharmaceutically acceptable salts or solvates thereof, and their use as sensitizers for chemotherapy of malignant tumors.

  本发明涉及含有Formula I的羟肟基团的5-成员杂芳化合物，其药用可接受盐或溶剂，以及它们作为恶性肿瘤化疗的增敏剂的用途。
• METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE
  申请人：Kwak Woo Young

  公开号：US20120016126A1

  公开（公告）日：2012-01-19

  The present invention relates to an improved method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention allows reduction of production costs by reacting low cost reagents, improves yield and is adaptable for mass production.

  本发明涉及一种改进的二肽基胰岛素释放肽酶-IV抑制剂及中间体制备方法。本发明通过使用低成本试剂反应，降低生产成本，提高产量，并适用于大规模生产。